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OBJECTIVES: To evaluate cardiovascular involvement in children and adolescents with End Stage Renal Disease
(ESRD) and to characterize the main risk factors associated with this outcome.
METHODS: Cross-sectional study of 69 children and adolescents at renal transplantation and 33 healthy
individuals matched by age and gender. The study outcomes were left ventricular mass z-score (LVMZ) and
carotid artery intima-media thickness (CIMT). The potential risk factors considered were age, gender, CKD
etiology, use of oral vitamin D and calcium-based phosphate binders, systolic and diastolic blood pressure,
body mass index z-score, time since diagnosis, dialysis duration, serum levels of ionic calcium, phosphorus,
parathyroid hormone, fibroblast growth factor (FGF 23), uric acid, homocysteine, cholesterol, triglycerides,
C-reactive protein (CRP), vitamin D and hemoglobin.
RESULTS: In the multivariate analysis, the factors associated with LVMZ were dialysis duration, age, systolic
blood pressure, serum hemoglobin and HDL cholesterol levels. Regarding CIMT, in the multivariate analysis,
systolic blood pressure was the only factor associated with the outcome.
CONCLUSION: Children exhibited important cardiovascular involvement at the time of the renal transplanta-
tion. Both of the studied outcomes were independently associated with systolic blood pressure. For this reason,
controlling blood pressure seems to be the main therapy to minimize cardiovascular involvement in children
with ESRD.
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’ INTRODUCTION
Chronic kidney disease (CKD) is a public health concern
for adult and pediatric patients (1). In 2010, 2,618 million
people in the world underwent renal replacement therapy
(RRT) (2), and the prevalence of children undergoing RRT in
Brazil was 20 cases per million individuals in this age group
in 2012 (3).
Cardiovascular disease (CVD) is a leading cause of death
in pediatric CKD patients (4-7). In children undergoing
dialysis, the mortality associated with cardiac disease is one
thousand times higher than in normal children (7). CVD was
the main cause of death in patients undergoing dialysis,
affecting 33% of cases in a cohort of US children followed
from 1995 to 2010 (8).
In adults with CKD, CVD results from an interaction of risk
factors that are grouped into a) traditional factors, such as
hypertension, diabetes, hypercholesterolemia, smoking, seden-
tary lifestyle, white ethnicity, aging, glucose intolerance,
psychosocial stress, family history of heart disease, malnutri-
tion, obesity and male gender; and b) non-traditional
factors associated with CKD (9,10). The CKD associated
factors are either hemodynamic (volume overload, arter-
iovenous fistula and anemia) or metabolic, such as oxida-
tive stress; inflammation; hyperhomocysteinemia; proteinuria;
increased renin-angiotensin-aldosterone activity; abnormal
calcium, phosphorus and vitamin D metabolism; increa-
sed serum FGF-23 levels; dyslipidemia; hypoalbuminemia;
increased pro-thrombotic factor levels; endothelial dysfunc-
tion and infection (Chlamydia pneumoniae) (11). When com-
pared to adult patients, children with CKD are less exposed
to traditional risk factors (12), which allows for privileged
observation of the role of non-traditional factors.
Considering that infarction and stroke are late events not
usually experienced in the pediatric age range, we evaluatedDOI: 10.6061/clinics/2019/e859
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cardiovascular changes in children and adolescents with
CKD at the time of renal transplantation (RT), considering
echocardiography and carotid ultrasound as surrogate end-
points, i.e., substitutes for late clinical events. These changes
have already been described in children and adolescents in
economically developed countries, but reports are scarce in
countries in the southern hemisphere.
The present study aimed to evaluate cardiovascular invol-
vement in children and adolescents with ESRD at the time
of (RT) using echocardiography and carotid ultrasound.
Additionally, we aimed to characterize the main risk factors
associated with these outcomes.
’ METHODS
We performed a cross-sectional study of 69 patients aged
18 years or less who underwent (RT) at Hospital do Rim-
UNIFESP. A control group of healthy children paired by sex
and age who were treated in the adolescents outpatient
service from the same institution was also included. The data
were collected from March 2012 to December 2014.
The study was approved by the Ethics and Research
Committee of the Federal University of São Paulo (Protocol
2031/11). All patients enrolled in the study signed a consent
form.
The exclusion criteria were: congenital or structural cardiac
abnormalities and primary myocardial disease; children with
active infectious disease, characterized by fever and bacter-
emia, or under antimicrobial treatment; diabetes, active
inflammatory diseases (e.g., vasculitis and systemic lupus
erythematosus), or genetic or endocrine diseases with dis-
orders in calcium or phosphorus metabolism; smoking
(in adolescents); and the presence of a venous catheter near
the carotids.
Left ventricular mass z-score (LVMZ) measured by echo-
cardiography and carotid artery intima-media thickness (CIMT)
measured by carotid ultrasound in both groups were expressed
as a continuous quantitative variable.
The following risk factors were considered: age at trans-
plantation, gender, body mass index z-score, time (months)
since CKD diagnosis, duration (months) of dialysis before
the renal transplantation, etiology of the CKD (undeter-
mined, urinary tract malformation, glomerulopathies, other
diagnoses), systolic blood pressure (SBP), diastolic blood
pressure, serum hemoglobin levels, serum albumin levels,
serum total cholesterol levels, serum HDL cholesterol levels,
serum triglycerides levels, C-reactive protein (CRP), uric acid,
homocysteine, serum ionic calcium levels, serum phosphorus
levels, serum calcium x phosphorus product levels (CaxP
product), serum parathyroid hormone (PTH) levels, serum
fibroblast growth factor (FGF23) levels, serum vitamin D
levels, vitamin D use and use of calcium-based phosphate
binders (categorically evaluated as yes or no, with no con-
firmation of the time of use or adherence).
To prevent the requirement of invasive and painful
procedures in healthy individuals, blood sampling was not
performed in the control group.
Evaluation of the Left Ventricular Mass Z-Score
Outcome
After a median follow-up of 24 days (IQR=16 to 30)
following RT transthoracic color Doppler echocardiography
was performed by 1 of 2 expert physicians using a standard
VIVID 7 dimension device (General Electrics Healthcare)
with a 5-mHz transducer. To calculate the left ventricular
mass Z-scores (LVMZ), Parameter Z software was used
according to the American Society of Echo’s Guidelines and
Standards for Performance of a Pediatric Echocardiogram (13).
We used American Society of Echocardiography guide-
lines (iASE version 3.0.4) to evaluate the left ventricular mass
index (LVMI), including relative wall thickness and left
ventricular geometry. Diastolic dysfunction was evaluated
with tissue Doppler and expressed as a binary variable
(present or absent diastolic dysfunction) (14).
Evaluation of Carotid Artery Intima-Media
Thickness
All ultrasound exams were performed by the same
examiner using a 3-12-MHz multi-frequency linear transdu-
cer device (LOGIQ 7, General Electric Health Cares). The
patients were maintained in slight neck hyperextension with
the chin slightly rotated laterally in the opposite direction to
the transducer after at least ten minutes of rest (15).
The CIMT measure was defined as the distance between
the edges of the lumen-intimal interface and the medial-
adventitial interface of the distal wall, measured bilaterally in
the common carotid artery 1 cm below the bifurcation (16).
Two measures were manually performed with the caliper
method on each artery scan and the mean of the results was
calculated.
For the control group, the echocardiogram and carotid
ultrasound were obtained using the same methodology as
for the study group.
Statistical Analysis
The data were expressed as the mean and standard
deviation or median and interquartile range (IQR) according
to the distribution of the variables. To compare the two
groups, we used Student’s t-test for quantitative variables
and the chi-squared test or Fisher’s exact test for proportions.
To evaluate a possible association between risk factors and
outcomes (left ventricular mass z-score and carotid artery
intima-medial thickness), a simple linear regression model
was used for each outcome. Then, variables with po0.10 in
the simple linear regression were selected for inclusion in a
multivariate linear regression model. In the multivariable
models we included up to 5 potential risk variables to respect
the proportion of introducing one risk variable for each 10 to
15 individuals in the sample. The covariables that did not
exhibit a significant association with the studied outcome
were removed one by one (i.e., the backward selection
method). Lastly, the interaction terms between the variables
that remained in the final models were investigated.
For all of the tests, a limit of po0.05 was adopted to reject
the null hypothesis, and all calculations were performed
using Stata software 14.2s (College Station, TX77845, USA).
The study was approved by the Ethics and Research
Committee of the Federal University of São Paulo (Pro-
tocol 2031/11). All patients enrolled in the study signed a
consent form.
’ RESULTS
During the data collection, there were 79 pediatric trans-
plants, with all the recipients being candidates for participa-
tion in the study. Two refused to participate and eight were
excluded, four for infections and four because they did not
attend the hospital for the examinations.
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The demographic, anthropometric and clinical data of
the study sample are presented in Table 1. There were no
significant differences regarding age or sex between the
groups, whereas the weight, height and BMI z-score were
significantly lower in ESRD children.
Regarding the etiology of CKD, there were 26 cases of
urinary tract malformations (38%), 16 cases of glomerulo-
pathies (23%), 23 cases of undetermined diseases (33%) and
four children with other diagnoses (6%).
The median time span since the CKD diagnosis to RT was
35 months (IQR=13–72), and the median duration of RRT
was 14 months (IQR=8–23). In 7/69 cases (10%), a preemp-
tive RT was performed. Among the remaining 62 patients,
the dialysis methods were exclusive hemodialysis (HD)
in 35 patients (51%), exclusive peritoneal dialysis (PD) in
14 cases (20%), and both HD and DP in 13 (19%) cases.
Regarding the type of RT, 65 children (94%) received a
deceased-donor kidney.
The blood pressure values were higher among ESRD
children when compared to controls. Among cases, 44
patients (64%) used antihypertensive drugs and 16 had
stage 1 hypertension (17), 9 had stage 2, 5 were pre-
hypertensive, and 14 had normal blood pressure. In the
group of patients not using antihypertensive drugs, 4 had
high blood pressure levels: two with stage 1 hypertension,
one with stage 2, and one with pre-hypertension. None of
the individuals from the control group required hyper-
tension medication, and all of them had normal blood
pressure.
Echocardiographic Parameters
The left ventricular mass z-score (LVMZ) was 0.48
(SD=1.75) in CKD patients and -0.94 (SD=1.00) in patients
from the control group, displaying a significant difference
between groups (Figure 1). The LVMZ was increased (42) in
14 patients among cases (20%) and in no individuals from
the control group.
Among patients with CKD, 42 children (60.9%) exhibited
normal left ventricular geometry, whereas concentric hyper-
trophy was observed in 14 patients (20.3%), eccentric hyper-
trophy in 11 patients (15.9%) and concentric remodeling in
Table 1 - Demographic, anthropometric and clinical data of the sample according to the study group.
Variable Cases (n=69) Controls (n=33) p
Mean Age in Years (SD) 13.1 (4.6) 13.0 (3.7) 0.967
Gender (Male/Female) 39/30 17/16 0.635
Mean Weight in kg (SD) 38.4 (17.1) 47.6 (14.3) 0.009
Mean Height in cm (SD) 141.7 (25.6) 152.1 (18.5) 0.042
H/A Z-Score (SD) -1.6 (1.5) -0.1 (0.9) o0.001
BMI Z-Score (SD) -0.6 (1.5) 0.3 (0.8) 0.001
Pubescent/Pre-pubescent 40/17 25/8 0.568
Months Since Diagnosis (IQR) 35 (13 to 72) NA NA
Months Undergoing Dialysis (IQR) 14 (8 to 23) NA NA
Urinary Tract Malformation (n/total) 26/69 NA NA
Systolic Blood Pressure (mmHg) 122 (21) 99 (11) o0.001
Diastolic Blood Pressure (mmHg) 76 (15) 59 (9) o0.001
SD-Standard deviation of the mean, H/A-Height/Age, BMI-Body mass index, NA-Not applicable, IQR-Interquartile range of the median.
Figure 1 - Left ventricular Z-score according to study group.
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two other (2.9%). Conversely, all individuals from control
group had normal left ventricular geometry (po0.001).
The left ventricular systolic function was preserved in all
of the patients, except for one case that exhibited moderate
dysfunction. All of the controls had normal function. The
analysis of the diastolic function was not possible in one case
due to tachycardia. Nine patients with CKD (13%) exhibited
altered diastolic dysfunction (13%), whereas controls were
normal (po0.001).
The results of the univariate and multivariate linear
regression are compiled in Table 2.
In this model, among all the nine pre-selected covariables,
we opted to exclude four in order to comply with the pro-
portion of including one counfounder for each ten to fifteen
individuals in the sample. Hence, we excluded DBP because
it was strongly correlated with SBP and also etiology of the
CKD, serum FGF23 and vitamin D use because these were
the variables with less previously published evidence to
explain changes in left ventricular mass. All the selected five
factors showed a significant association with LVMZ in this
model: dialysis duration, age at transplantation, SBP, serum
hemoglobin levels and serum HDL levels. The details of
these associations are as follows: for each 1-month increase in
dialysis duration, a 0.017 SDS increase in LVMZ is observed;
for each additional year of age at RT, a 0.08 SDS increase in
LVMZ is expected; each 1 mmHg increase in SBP is asso-
ciated with a 0.024 SDS increase in LVMZ; for each 1 g/dL
increase in serum hemoglobin, a 0.20 SDS decrease in LVMZ
is expected; and for each 1 mg/dL increase in HDL, a
decrease of 0.04 SDS in LVMZ is predicted. The analysis of
the interaction between these variables did not show
significant effects, suggesting that these associations with
LVMZ are independent.
Analysis of the Carotid Artery Intima-Medial
Thickness
When comparing the carotid artery intima-medial thick-
ness (CIMT), we found a significant difference between the
groups, with a greater thickness in patients with ESRD
(0.52±0.10 mm versus 0.46±0.07 mm, p=0.028). This result
demonstrates arterial involvement in children with ESRD, as
illustrated in Figure 2. The linear regression analyses for this
outcome are compiled in Table 3.
Age, SBP, diastolic blood pressure (DBP) and vitamin D
use exhibited an association with CIMTand were included in
the multivariate linear regression model, after which there
was only an association with SBP. According to this analysis,
each 10-mmHg increase in SBP was associated with an
increase of 0.015 mm in CIMT.
’ DISCUSSION
The main finding of the present study was that ESRD
children and adolescents exhibited cardiovascular involve-
ment at the time of RT presenting increased LVM and CIMT
when compared to controls. Such outcomes are substitutes
for late clinical events at the pediatric age range. However,
these outcomes are relevant because they are recognized
risk factors for predictable clinical outcomes, especially in
adults (18,19).
Cardiac abnormalities are frequent in adults and children
with CKD and contribute to morbidity (7,9,20). In adults,
a prospective study evaluating 161 patients undergoing
HD showed that each 1 g/m2.7 increase in LVMI was
associated with a 62% increase in the risk of adverse
cardiovascular events. This association suggests that
changes in LVM have independent prognostic value for
cardiovascular events, reinforcing echocardiography as a
tool for monitoring cardiovascular risk in patients under-
going dialysis (21).
Left ventricular hypertrophy (LVH) is common in pediatric
and adult patients undergoing dialysis (9). This change may
occur early and has a prevalence ranging from 30% in mild to
moderate CKD (22) to 73% in children undergoing dialysis
(23-26). There are different methods for indexing LVM,
a topic that is widely discussed in the literature (22,25,27).
Table 2 - Univariate and multivariate linear regression analysis of risk factors associated with left ventricular mass Z-score.
Variable Coefficient CI p Coefficient CI p
Age 0.084 0.013 to 0.155 0.020 0.083 0.009 to 0.157 0.028
Gender -0.334 -1.008 to 0.339 0.328
Body Mass Index (BMI) -0.055 -0.362 to 0.251 0.720
Time Since Diagnosis 0.000 -0.008 to 0.008 0.991
Dialysis Duration 0.017 -0.002 to 0.037 0.082 0.017 0.002 to 0.031 0.020
Urinary Tract malformation -0.755 -1.562 to 0.050 0.066 NS
Systolic Blood Pressure 0.038 0.024 to 0.051 0.000 0.024 0.005 to 0.043 0.011
Diastolic Blood Pressure 0.045 0.025 to 0.065 0.000 NS
Serum Hemoglobin (g/dL) -0.214 -0.416 to -0.013 0.037 -0.204 -0.379 to -0.028 0.023
Serum Albumin (g/dL) 0.310 -0.255 to 0.876 0.277
Serum Cholesterol (mg/dL) -0.002 -0.011 to 0.006 0.555
Serum HDL (mg/dL) -0.048 -0.086 to -0.011 0.012 -0.040 -0.075 to -0.005 0.026
Serum TG (mg/dL)) 0.002 -0.002 to 0.006 0.377
Serum CRP (mg/dL) 0.157 -0.234 to 0.549 0.425
Serum Uric Acid (mg/dL) -0.064 -0.289 to 0.160 0.570
Serum Homoc (mmol/dL) 0.011 -0.033 to 0.568 0.613
Serum Ionic Calcium(mg/dL) -4.065 -8.990 to 0.859 0.104
Serum Phosphorus (mg/dL) 0.166 -0.101 to 0.434 0.219
CaxP Product (mg/dL) 0.010 -0.019 to 0.040 0.475
Serum PTH (pg/mL) 0.000 -0.000 to 0.001 0.145
Serum FGF23 (pg/mL) 0.000 0.000 to 0.000 0.038 NS
Serum Vitamin D (ng/dL) 0.011 -0.021 to 0.043 0.500
Vitamin D Use 0.806 -1.674 to 0.062 0.068 NS
Use of Phosphate Binders -0.130 -1.106 to 0.845 0.790
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In this research, considering that LVM is influenced by the
age and size of pediatric patient, we opted to use the LVM z
score to express the magnitude of the deviation from the
mean (28). In study involving children in different stages of
CKD, the use of the z-score allowed for the identification a
higher LVH proportion in the dialysis group when compared to
other criteria, such as LVM indexed to body surface area (27).
The first variable that exhibited an independent associa-
tion with LVMZ was age at RT, which is biologically
plausible. However, because we use the z score to express
the LVM, the effect of age on any body size measurement
was attenuated. Therefore, this association is likely related to
CKD and not simply due to LVM increase with age. In
addition to age, we observed the effect of dialysis duration
on LVMZ and it is possible that the association between LVM
and age is somehow related to dialysis duration. In contrast
to our findings, the association between LVM and dialysis
duration was not found in another study involving
64 patients undergoing dialysis (29). However this study
was retrospective, and we believe that our finding highlights
the importance of limiting dialysis duration and encouraging
preemptive RT to decrease the frequency of LVH.
Figure 2 - Carotid artery intima-medial thickness according to study group.
Table 3 - Univariate and multivariate analysis of risk factors associated with left carotid artery intima-medial thickness.
Variable Coefficient CI p Coefficient CI p
Age 0.005 0.001 to 0.010 0.013 0.003 -0.001 to 0.008 0.122
Gender -0.013 -0.050 to 0.023 0.478
Body Mass Index (BMI) -0.008 -0.021 to 0.003 0.168
Time Since Diagnosis -0.000 -0.000 to 0.000 0.559
Dialysis Duration -0.000 -0.001 to 0.000 0.733
Urinary Tract Malformation -0.021 -0.066 to 0.024 0.364
Systolic Blood Pressure 0.001 0.000 to 0.002 0.001 0.001 0.000 to 0.002 0.009
Diastolic Blood Pressure 0.001 0.000 to 0.003 0.001 0.000 -0.001 to 0.003 0.532
Serum Hemoglobin (g/dL) -0.005 -0.016 to 0.004 0.251
Serum Albumin (g/dL) 0.022 -0.006 to 0.050 0.122
Serum Cholesterol (mg/dL) -0.000 -0.000 to 0.000 0.176
Serum HDL (mg/dL) 0.001 -0.000 to 0.003 0.181
Serum TG (mg/dL) -0.000 -0.000 to 0.000 0.181
Serum CRP (mg/dL) -0.004 -0.020 to 0.010 0.535
Serum Uric Acid (mg/dL) 0.001 -0.013 to 0.015 0.881
Serum Homoc (mmol/dL) 0.002 -0.001 to 0.006 0.251
Serum Ionic Calcium (mg/dL) 0.078 -0.134 to 0.291 0.467
Serum Phosphorus(mg/dL) -0.006 -0.023 to 0.010 0.450
CaxP Product (mg/dL) -0.000 -0.002 to 0.001 0.649
Serum PTH (pg/mL) -0.000 -0.000 to 0.000 -0.500
Serum FGF23(pg/mL) -0.000 -0.000 to 0.000 0.684
Serum Vitamin D (ng/mL) -0.000 -0.001 to 0.001 0.924
Vitamin D Use -0.058 -0.103 to -0.013 0.011 -0.031 -0.081 to 0.019 0.221
Use of Phosphate Binders 0.024 -0.025 to 0.074 0.333
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Another finding was the association between serum hemo-
globin and LVM, which is consistent with data from the
literature that reports an association between anemia and
LVMI (22,30). In a cross-sectional study evaluating 156
children undergoing dialysis with similar mean age to that of
our study, an independent association between low serum
hemoglobin and LVMI was reported (22). In agreement to
these findings, a more recent study on 46 patients under-
going dialysis also showed anemia and hypertension as pre-
dictive factors of LVMI in patients 5 to 21 years of age (30).
Amongst the potential risk factors tested in the present
study, only SBP exhibited an association with both of the
studied outcomes. This finding agrees with most studies in
the literature (22,24,31,32) and has implications for daily
clinical practice, reinforcing the need for strict control of this
parameter in CKD patients. Specifically in children under-
going dialysis, an association between hypertension and
LVH was reported in another study on Brazilian children
(33). Moreover, if we consider that hypertension is common
in both the short- (34) and long term (35) following RT
in children, adequate diagnosis and treatment of this com-
plication has increased importance to reduce the risk for
cardiovascular complications in all stages of CKD. It is worth
noting that data from another cross-sectional study showed
an association between SBP and LVMI even in non-
hypertensive CKD patients, suggesting that the target in
current recommendations for controlling the SBP must be
reconsidered (24).
Low serum HDL is associated with increased coronary
disease in adults with CKD, and lower baseline concentra-
tions when compared to the general population have been
reported. These lipid abnormalities may produce a 1.2-
1.4-fold higher risk for coronary disease (36). Our findings
confirm the possibility that decreasing serum HDL choles-
terol in children increases LVM, which may have implica-
tions for the clinical treatment of these patients.
Previous studies have reported normal CIMT values
in children from the northern hemisphere (16,37) as well as
in Brazil (38). However, such studies are scarce and not
internationally validated. For this reason, we chose not to
calculate the CIMT z-score and our analyses were performed
with the absolute value of this measure. In a study that
evaluated patients aged between 10 and 20 years of age
without cardiovascular disease, associations between CIMT
and age and also between body size and blood pressure were
observed in healthy adolescents (16). Similarly, in a European
multicenter study, a significant relationship was found
between the SBP z-score and BMI as independent positive
predictors associated with CIMT (37).
In a study evaluating 101 children aged between 2 and 18
years of age and healthy controls, dyslipidemia and hyper-
tension were associated with an increase of in the CIMT, (39).
We also found a significant association between SBP with
CIMT, and there was no association with calcium, phos-
phorus, gender or CKD etiology, which is similar to the
findings of Litwin et al. (12).
The results of the present study must be interpreted
considering its limitations. The first is the cross-sectional
design of the study, which prevents the establishment of
causal relationships between risk factors and the studied
outcomes. The development of cardiovascular complications
is a process that occurs over time, and cross-sectional studies,
only one time point in this progression can be evaluated.
Another study feature that prevented us from formulating
more in-depth analyses was the lack of data on both dialysis
quality and the duration of the medications that the patients
were receiving. The fact that patients of the study had been
referred for from different regions of the country precluded
access to their medical records in the dialysis clinics of origin,
rendering it impossible to obtain data on prescription dura-
tion, changes in dosages and adherence. This factor limited
our analysis of the role of dialysis quality and the use of
calcium-based phosphate binders, vitamin D analogs and
antihypertensive medications.
Nevertheless we believe that our findings indicate that
there is significant cardiovascular involvement in at least
1/5 of pediatric ESRD patients at the time of RT. We
concluded that children with CKD show cardiac involve-
ment and that the control of modifiable risk factors as hyper-
tension and anemia must be considered therapeutic aims.
The independent association between SBP and both markers
suggests an opportunity for interventions that aim to prevent
cardiovascular complications.
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